Abiomed Announces New PROTECT II Data at Society for Cardiovascular Angiography Interventions 2011 Scientific Sessions

Abiomed, Inc. ABMD today announced results from further 90 day clinical and economic analyses, based on data from the PROTECT II study. The analyses showed a significant reduction of 29% in the Major Adverse Cardiac and Cerebrovascular Event rate for the Impella® arm at 90 days. Additionally, the Impella patient population had overall average hospital charge savings of $19,000 to $22,000 without device costs included. With the device costs included, hospital charges with Impella ranged from being equivalent to $3,000 less than the intra-aortic balloon pump.